Clinical Trial Update: Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating oral apremilast for moderate to severe plaque psoriasis has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Apremilast (apremilast)

Snippet

Sponsor: Amgen | Conditions: Plaque Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2014-11-05